Vestech developing new BPH treatment

Vestech has been assisting Prostacare P/L, the owners and developers of a novel treatment for Benign Prostatic Hypertrophy (BPH), in the development of their product including the IP strategy and working towards regulatory approval under CE Marking and through the FDA. Working with the German vendors and the Singaporean based clinical researchers, Vestech has been tasked with bringing the device to fruition and achieving market entry.

Share
No comments yet.

Leave a Reply